Collectively, PaCa patients with both high PD-L1 and B7-H4 might be dismissed from the immunotherapy in clinical practice. This evidence concerns the gene VTCN1 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.